EP3765024
Ný lyfjasamsetning sem inniheldur tvíþætt NK-1/NK-3 viðtaka-mótlyf.
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
13.3.2019EP published:
22.11.2023EP application number:
19711866.4
EP translation filed:
12.2.2024Grant published:
15.3.2024EPO information:
European Patent Register
Max expiry date:
12.3.2039Expiry date:
12.3.2027Next due date:
31.3.2027
Title in English:
NOVEL PHARMACEUTICAL FORMULATION COMPRISING DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS.Language of the patent:
English
Timeline
Today
13.3.2019EP application
22.11.2023EP Publication
12.2.2024Translation submitted
15.3.2024Registration published
12.3.2027Expires
Owner
Name:
KaNDy Therapeutics LimitedAddress:
400 South Oak Way, Reading, Berkshire RG2 6AD, GB
Inventor
Name:
TROWER, MikeAddress:
Stevenage Hertfordshire SG1 2FX, GB
Name:
KERR, MaryAddress:
Stevenage Hertfordshire SG1 2FX, GB
Name:
ELDER, DavidAddress:
Hertford, Hertfordshire SG14 2DE, GB
Name:
LAZARO, MonicaAddress:
St. Petersburg, Florida 33716, US
Name:
BUSH, DerekAddress:
St. Petersburg, Florida 33716, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862642622 PDate:
14.3.2018Country:
US
Classification
Categories:
C07D 498/04, A61P 5/24, A61K 31/5383, A61K 9/08, A61K 9/48, A61K 47/14, A61P 25/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 23.2.2024
Expires: 12.3.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 26.2.2025
Expires: 12.3.2026
Payer: Árnason Faktor ehf.
Number: 8
Paid: 12.3.2026
Expires: 12.3.2027
Payer: Árnason Faktor ehf.